Foster Stockbroking bullish on SDI
Foster Stockbroking has initiated coverage of SDI with a buy recommendation and a 12 month price target of $1.36, a premium of 80% to Friday’s closing price of 75.5 cents.
It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
Founded in 1971, SDI is Australia’s largest dental manufacturer with prominent positions in the areas of amalgam, whitening, aesthetics and equipment.
There has been a significant change in product mix in terms of revenue contribution over the last five years with less reliance on the volatile amalgam business and more of a focus on aesthetics.
While there is a large differential between the company’s recent trading range and the price target, the latter isn’t significantly higher than the group’s 12 month high of $1.16 that was struck just prior to providing a trading update in November that was poorly received.
Earnings skewed to the second half
Management’s main message in providing the trading update was that earnings would be skewed to the second half of the year and that the net profit after tax for the first half would be in a range between $2 million and $2.5 million compared with the previous corresponding period’s $3 million.
Management provided context at the time regarding the skew in earnings, as well as the potential for the foundations for long-term growth to be achieved in March 2017 when the group will have the opportunity to showcase its new products in Germany where it has distribution facilities.
With regard to the first six months, SDI Chief Executive Ms Samantha Cheetham said, “The first six months have traditionally been weaker than the second and I expect the second half will improve and I am confident of meeting our targets”.
Looking to the future, Cheetham said, “Our current focus is on the launch of new products in the second half and these will be showcased at the world’s largest industry trade show to be held in Germany in March 2017, underpinning future growth for the business and highlighting the research and development investments made”.
R&D and IP to drive future earnings and provide barriers to entry
This illustrates the increasing emphasis of research and development, as well as intellectual property in terms of driving the business. Foster Stockbroking sees this as an advantage, and the broker also highlighted that industry regulation is a key barrier to entry.
Taking a five-year view on SDI and eliminating foreign exchange variations, Foster said, “With the increasing momentum in non-amalgam products, we would not be surprised to see growth of more than 10% per annum”.
The broker initiated coverage with a buy recommendation and is forecasting a net profit of $7 million in fiscal 2017, increasing nearly 20% to $8.3 million in fiscal 2018.
This implies fiscal 2018 earnings per share of 7 cents, placing the company on a PE multiple of 10.8 relative to Friday’s closing price.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.